Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326 | Completed Phase 3 Results FDA Drug

• 1 other identifier: H-39600
• Study Type: interventional
• Target: 137
• Locations: 1 country
• Sites: 1

Brief Summary

Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge. This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.

Conditions

Type 2 Diabetes Treated With Insulin

Keywords

Fiasp; Novolog; Continuous glucose monitor (CGM); Hypoglycemia; Hyperglycemia; Hemoglobin A1c

Outcome Measures

Primary Outcomes (1)

• Postprandial Glucose Control

  Percent of time spent in the glycemic target range of 100-180 mg/dL in the 4 hour postprandial period will be assessed using a continuous glucose monitoring (CGM) system.

  3 days

Secondary Outcomes (8)

• Glycemic Control While Hospitalized

  3 days

• Percent of Time Spent in Glycemic Range of 70-140 mg/dL

  3 days

• Percent of Time Spent With Hypoglycemia During Hospitalization

  3 days

• Percent of Nocturnal Time in Glycemic Target Range 100-180 mg/dL

  3 days

• Percent of Nocturnal Time Spent With Hypoglycemia

  3 days

Study Arms (2)

Group 1 insulin glargine and Novolog

ACTIVE COMPARATOR

Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.

Drug: Insulin glargine; Drug: NovoLog; Other: Standard carbohydrate diet

Group 2 insulin glargine and Fiasp

EXPERIMENTAL

Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.

Drug: Insulin glargine; Drug: Insulin Fiasp; Other: Standard carbohydrate diet

Interventions

Insulin glargine DRUG

Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%

Also known as: Lantus®

Group 1 insulin glargine and Novolog; Group 2 insulin glargine and Fiasp

NovoLog DRUG

Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

Also known as: NovoLog®

Group 1 insulin glargine and Novolog

Insulin Fiasp DRUG

Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

Also known as: Fiasp®

Group 2 insulin glargine and Fiasp

Standard carbohydrate diet OTHER

Standard carbohydrate diet as per usual hospital care (75g with each meal)

Group 1 insulin glargine and Novolog; Group 2 insulin glargine and Fiasp

Eligibility Criteria

• Age: 21 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• English-speaking
• Males and female adult subjects admitted to Boston Medical Center to a medical or surgical floor.
• Consultation by the Inpatient Diabetes Service at Boston Medical Center is required prior to consent.
• Age ≥ 21 and \<= 80 years.
• Diagnosed with type 2 diabetes at least 180 days prior to screening.
• Hyperglycemia during admission, as defined by a point of care and/or venous blood glucose ≥ 140 mg/dL.
• Prior to admission subjects must be using one of the following for outpatient diabetes management:
• Insulin
• ≥ 2 oral/injectable agents
• One oral/injectable agent with a hemoglobin A1c of ≥ 8% within 3 months of enrollment.
• Patients who are expected to remain hospitalized for a minimum of 48 hours following CGM sensor placement.
• BMI \<45 kg/m\^2.

You may not qualify if:

• Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA).
• Treatment or plan for treatment with glucocorticoids during the index hospitalization.
• Female patients who are pregnant (tested during hospitalization or screening) or breast-feeding during the hospitalization.
• Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery.
• Prior diagnosis of gastroparesis or cirrhosis.
• Acute or chronic kidney disease with a serum creatinine of ≥ 2 mg/dL at the time of screening.
• Clinically significant nausea and/or vomiting or unable to consume more than 30 grams of carbohydrate at each meal.
• Patients expected to receive nothing by mouth (NPO) for \>24 hours.
• Use of continuous or intermittent enteral feeding or parenteral nutrition.
• Patient receiving aspirin and/or vitamin C during the hospitalization.
• Any mental condition rendering the subject unable to provide informed consent.
• Patients currently incarcerated.
• Patients using \>1 unit/kg/day of insulin prior to admission.
• Insulin pump usage within the 2 weeks prior to or during admission.
• Patients currently using real-time continuous glucose monitoring (CGM) or personal flash glucose monitoring system (FGM).

Sponsors & Collaborators

• Boston Medical Center: lead
• Novo Nordisk A/S: collaborator

Study Sites (1)

Boston Medical Center

Boston, Massachusetts, 02118, United States

Location

MeSH Terms

Conditions

Hypoglycemia; Hyperglycemia

Interventions

Insulin Glargine; Insulin Aspart

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Insulin, Long-Acting; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Insulin, Short-Acting

Results Point of Contact

• Title: Sara M Alexanian, MD
• Organization: Boston Medical Center

sara.alexanian@bmc.org

617-638-8545

Study Officials

• Sara M Alexanian, MD

  Boston Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2020
• First Posted: July 7, 2020
• Study Start: December 7, 2020
• Primary Completion: May 27, 2023
• Study Completion: May 27, 2023
• Last Updated: March 19, 2024
• Results First Posted: March 19, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)